862700-70-7

Basic information

• Product Name: 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one
• Synonyms: 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one;S-Deoxo-3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)-6-oxo-fulvestrant
• CAS NO: 862700-70-7
• Molecular Formula: C₄₂H₆₁F₅O₅S
• Molecular Weight: 772.987756
• Product Categories: Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Sulfur & Selenium Compounds
• Mol File: 862700-70-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Diethyl Ether, Ethyl Acetate
• CAS DataBase Reference: 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one(862700-70-7)
• EPA Substance Registry System: 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one(862700-70-7)

Safety Data

• Hazardous Substances Data: 862700-70-7(Hazardous Substances Data)

Usage

Description

7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one is a complex organic compound that is a derivative of Fulvestrant (F862500) impurity E. It is characterized by its unique chemical structure, which includes a pentafluoropentyl group, a nonyl group, and two tetrahydro-2H-pyran-2-yl groups. 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one is a yellow oil, indicating its non-crystalline nature.

Uses

Used in Pharmaceutical Industry:
7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]--3,17β-bis-(O-tetrahydro-2H-pyran-2-yl)estra-1,3,5(10)-triene-6-one is used as an intermediate in the preparation of antiestrogenic 17-alkylene-16α-hydroxyestratrienes for cancer treatment. Its unique chemical properties make it a valuable component in the development of pharmaceuticals targeting estrogen receptor-positive breast cancer.
As a Fulvestrant (F862500) impurity E derivative, this compound plays a crucial role in the synthesis of antiestrogenic agents, which are essential in the treatment of hormone-sensitive cancers. The presence of the pentafluoropentyl and nonyl groups, along with the tetrahydro-2H-pyran-2-yl groups, contribute to the compound's ability to modulate estrogen receptor activity, thereby exerting an antiestrogenic effect.

Upstream product

• 862700-63-8 1-iodo-9-(4,4,5,5,5-pentafluoro-pentylsulfanyl)-nonane 
• 53573-82-3 3,17β-bis(2-tetrahydropyranyloxy)estra-1,3,5(10)-triene-6-one 
• 862700-61-6 thiobenzoic acid S-(4,4,5,5,5-pentafluoro-pentyl)ester 
• 148043-73-6 4,4,5,5,5-pentafluorpentan-1-ol 
• 122566-22-7 (8R,9S,13S,14S,17S)-13-Methyl-3,17-bis-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-ol 
• 55362-80-6 9-bromononan-1-ol 
• 76334-30-0 9-iodononan-1-ol 
• 862700-62-7 methanesulfonic acid 9-(4,4,5,5,5-pentafluoro-pentyl-sulfanyl)-nonyl ester 

Downstream Products

• 153004-31-0 (+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol 
• 1107606-70-1 6-oxo-7α-[9-(4,4,5,5,5-pentafluoropentyl)thiononyl]estra-1,3,5(10)-triene-3,17β-diol 

Relevant articles and documents

Processes and intermediates for preparing fulvestrant

The present invention provides a method and an intermediate for preparing fulvestrant, and relates to a method for preparing fulvestrant, and an intermediate (5) of fulvestrant, and a synthetic methodthereof. The method provided by the invention can be used for obtaining high-purity fulvestrant, and is suitable for industrial mass production.

Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol

The present invention provides a novel multi-step process for the manufacturing Fulvestrant, which is economical and convenient to operate at commercial scale, and requires only simple chromatographic separations after the coupling step of adding the side chain to the 7 position of the steroid.

STEROIDS FOR CANCER TREATMENT

The present invention relates to novel compounds which are 7α-substituted 17-alkylene-16α-hydroxy steroidal estrogens. This invention specifically relates to estrogen derivatives which contain 7α-substituents and which exhibit anti-estrogenic properties. The present invention also relates to use of said compounds as a medicament, and for the treatment of estrogen dependent disorders, a pharmaceutical composition comprising one or more of said compounds and a method of treatment.